🎉 M&A multiples are live!
Check it out!

Ultragenyx Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ultragenyx and similar public comparables like Pharming, Julphar, and Benevolent AI.

Ultragenyx Overview

About Ultragenyx

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.


Founded

2010

HQ

United States of America
Employees

1.3K+

Website

ultragenyx.com

Financials

LTM Revenue $588M

LTM EBITDA -$467M

EV

$2.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ultragenyx Financials

Ultragenyx has a last 12-month revenue of $588M and a last 12-month EBITDA of -$467M.

In the most recent fiscal year, Ultragenyx achieved revenue of $560M and an EBITDA of -$469M.

Ultragenyx expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ultragenyx valuation multiples based on analyst estimates

Ultragenyx P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $434M $560M XXX XXX XXX
Gross Profit $335M $389M XXX XXX XXX
Gross Margin 77% 69% XXX XXX XXX
EBITDA -$516M -$469M XXX XXX XXX
EBITDA Margin -119% -84% XXX XXX XXX
Net Profit -$707M -$607M XXX XXX XXX
Net Margin -163% -108% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ultragenyx Stock Performance

As of April 15, 2025, Ultragenyx's stock price is $35.

Ultragenyx has current market cap of $3.3B, and EV of $2.7B.

See Ultragenyx trading valuation data

Ultragenyx Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.7B $3.3B XXX XXX XXX XXX $-5.97

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ultragenyx Valuation Multiples

As of April 15, 2025, Ultragenyx has market cap of $3.3B and EV of $2.7B.

Ultragenyx's trades at 4.6x LTM EV/Revenue multiple, and -5.8x LTM EBITDA.

Analysts estimate Ultragenyx's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ultragenyx and 10K+ public comps

Ultragenyx Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.7B XXX XXX XXX
EV/Revenue 4.8x XXX XXX XXX
EV/EBITDA -5.8x XXX XXX XXX
P/E -5.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ultragenyx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ultragenyx Valuation Multiples

Ultragenyx's NTM/LTM revenue growth is 21%

Ultragenyx's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Ultragenyx's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ultragenyx's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ultragenyx and other 10K+ public comps

Ultragenyx Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 29% XXX XXX XXX XXX
EBITDA Margin -84% XXX XXX XXX XXX
EBITDA Growth -9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -63% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 125% XXX XXX XXX XXX
Opex to Revenue 182% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ultragenyx Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ultragenyx M&A and Investment Activity

Ultragenyx acquired  XXX companies to date.

Last acquisition by Ultragenyx was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ultragenyx acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ultragenyx

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ultragenyx

When was Ultragenyx founded? Ultragenyx was founded in 2010.
Where is Ultragenyx headquartered? Ultragenyx is headquartered in United States of America.
How many employees does Ultragenyx have? As of today, Ultragenyx has 1.3K+ employees.
Who is the CEO of Ultragenyx? Ultragenyx's CEO is Dr. Emil D. Kakkis, M.D.,PhD.
Is Ultragenyx publicy listed? Yes, Ultragenyx is a public company listed on NAS.
What is the stock symbol of Ultragenyx? Ultragenyx trades under RARE ticker.
When did Ultragenyx go public? Ultragenyx went public in 2014.
Who are competitors of Ultragenyx? Similar companies to Ultragenyx include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ultragenyx? Ultragenyx's current market cap is $3.3B
What is the current revenue of Ultragenyx? Ultragenyx's last 12-month revenue is $588M.
What is the current EBITDA of Ultragenyx? Ultragenyx's last 12-month EBITDA is -$467M.
What is the current EV/Revenue multiple of Ultragenyx? Current revenue multiple of Ultragenyx is 4.6x.
What is the current EV/EBITDA multiple of Ultragenyx? Current EBITDA multiple of Ultragenyx is -5.8x.
What is the current revenue growth of Ultragenyx? Ultragenyx revenue growth between 2023 and 2024 was 29%.
Is Ultragenyx profitable? Yes, Ultragenyx is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.